PIPELINE

Our pipeline

Our lead program to address the previously ‘undruggable’ MYC is in IND-enabling studies for MYC-dependent solid tumor cancers. Additional internal programs focus on other targets key to hematological and solid tumor cancers, as well as neurodegenerative disorders.